Speaking to European Medical Journal from the 19th Congress of the - TopicsExpress



          

Speaking to European Medical Journal from the 19th Congress of the European #Hematology Association (EHA) 2014 meeting, Prof Paul Richardson, Dana-Farber Cancer Institute, Boston, Masschusetts, USA, discusses results seen from the breakthrough PANORAMA 1 study, a global randomised, double-blind, placebo-controlled Phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma. Prof Richardson outlines the primary end-point results and side-effects observed, and comments on the clinical meaningfulness of these results. Results of sub-sets of higher risk groups are also discussed, and Prof Richardson comments on new data with ricolinostat (ACY-1215) in multiple myeloma.
Posted on: Tue, 09 Sep 2014 09:51:36 +0000

Trending Topics



Recently Viewed Topics




© 2015